PUBLISHER: The Business Research Company | PRODUCT CODE: 1946983
PUBLISHER: The Business Research Company | PRODUCT CODE: 1946983
Point-of-care (POC) coagulation testing devices are portable, easy-to-use medical devices used to assess the clotting ability of blood outside of a traditional laboratory setting. They are designed to provide rapid and accurate results, allowing healthcare providers to make immediate treatment decisions for patients with coagulation disorders or those at risk of abnormal bleeding or clotting.
The main products of point-of-care (POC) coagulation testing devices are coagulation monitors, consumables, and coagulation analyzers. Coagulation monitors are medical devices used to measure the clotting ability of blood, typically in a point-of-care (POC) setting. They work by using various technologies, including optical technology, mechanical technology, and electrochemical technology, and follow prothrombin time and international normalized ratio, viscoelastic coagulation monitoring, and other methods. The different applications include blood glucose testing, infectious diseases testing, cardiac markers testing, coagulation testing, blood gas and electrolyte testing, and others, and are used by hospitals, diagnostic laboratories, clinics, and others.
Tariffs are impacting the point-of-care coagulation testing devices market by increasing costs of imported sensors, microchips, reagents, optical components, and diagnostic consumables used in portable analyzers and test strips. Hospitals and diagnostic laboratories in North America and Europe are most affected due to dependence on imported precision components, while Asia-Pacific faces pricing pressure on device manufacturing and exports. These tariffs are increasing device costs and influencing procurement decisions across healthcare facilities. However, they are also encouraging regional manufacturing, localized reagent production, and supply chain diversification to improve long-term availability and cost stability.
The point-of-care (poc) coagulation testing devices market research report is one of a series of new reports from The Business Research Company that provides point-of-care (poc) coagulation testing devices market statistics, including point-of-care (poc) coagulation testing devices industry global market size, regional shares, competitors with a point-of-care (poc) coagulation testing devices market share, detailed point-of-care (poc) coagulation testing devices market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care (poc) coagulation testing devices industry. This point-of-care (poc) coagulation testing devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The point-of-care (poc) coagulation testing devices market size has grown strongly in recent years. It will grow from $2.32 billion in 2025 to $2.55 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to rising prevalence of coagulation disorders, increased use of anticoagulant therapies, expansion of decentralized healthcare settings, growing adoption of point-of-care diagnostics, improvements in coagulation testing technologies.
The point-of-care (poc) coagulation testing devices market size is expected to see strong growth in the next few years. It will grow to $3.49 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing demand for home healthcare diagnostics, rising focus on personalized medicine, expansion of telehealth-enabled diagnostics, growing geriatric population, continuous innovation in microfluidic testing platforms. Major trends in the forecast period include increasing adoption of portable coagulation monitors, rising demand for rapid diagnostic testing at point of care, growing use of home-based coagulation testing kits, expansion of wireless data connectivity in poc devices, enhanced focus on test accuracy and reliability.
The increasing prevalence of blood clotting disorders is expected to drive the growth of the point-of-care (POC) coagulation testing devices market in the coming years. Blood clotting disorders impair the blood's ability to clot properly, and lifestyle factors such as smoking, excessive alcohol consumption, and sedentary behavior can exacerbate these conditions by affecting blood vessel health, clotting factor levels, and blood flow, increasing the risk of abnormal clot formation. POC coagulation testing devices allow healthcare providers to rapidly assess a patient's coagulation status, enabling timely adjustments to medication dosages and treatment plans. For example, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, the number of patients living with hereditary haemophilia A (HMA) increased from 2,681 in 2022-2023 to 2,788 in 2023-2024. Therefore, the rise in blood clotting disorders is fueling the growth of the point-of-care coagulation testing devices market.
Major companies in the POC coagulation testing devices market are focusing on the development of immunofluorescence-based quantitative analyzers to enhance the diagnosis and management of coagulation disorders. Immunofluorescence-based quantitative analyzers are laboratory diagnostic instruments that measure and quantify specific proteins or molecules involved in the coagulation process, supporting accurate diagnosis and treatment of blood clotting disorders. For instance, in January 2023, Cipla Limited, an India-based pharmaceutical company, launched Cippoint, an immunofluorescence-based quantitative analyzer that provides rapid and precise test results within 3 to 15 minutes, enabling faster clinical decision-making. With its user-friendly interface, quick turnaround time, and broad testing capabilities, Cippoint improves diagnostic efficiency, supports timely clinical interventions, and enhances patient care outcomes.
In August 2024, Perosphere Technologies Inc., a US-based medical device manufacturer, partnered with M3 Medical, an Ireland-based medical device company, for an undisclosed amount. Through this partnership, the companies aim to improve patient outcomes, reduce healthcare system costs, and establish a new standard of care for patients using anticoagulant therapies or at risk of bleeding in Ireland.
Major companies operating in the point-of-care (poc) coagulation testing devices market are Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Bio-Rad Laboratories Inc., Werfen, Haemonetics Corporation, HemoSonics LLC, Sysmex Corporation, Nihon Kohden Corporation, HORIBA Medical, Helena Laboratories Corporation, Diagnostica Stago, Sekisui Diagnostics, Instrumentation Laboratory, Trinity Biotech plc, CoaguSense Inc., iLine Microsystems, Medirox AB, Hemochron Systems, Axis-Shield Diagnostics
North America was the largest region in the point-of-care (POC) coagulation testing devices market in 2025. The regions covered in the point-of-care (poc) coagulation testing devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the point-of-care (poc) coagulation testing devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The point-of-care (POC) coagulation testing devices market consists of revenues earned by entities by providing services such as increased patient comfort, improved workflow efficiency, better patient management, remote monitoring capabilities, emergency use for immediate testing, and assessment of anticoagulant reversal effectiveness. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care (POC) coagulation testing devices market also includes sales of viscoelastic testing devices, platelet function testing devices, and D-Dimer testing devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Point-of-Care (POC) Coagulation Testing Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses point-of-care (poc) coagulation testing devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for point-of-care (poc) coagulation testing devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The point-of-care (poc) coagulation testing devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.